Showing 1 - 20 results of 53 for search '(( significant decrease decrease ) OR ( ((significant small) OR (significant anti)) decrease ))~', query time: 0.47s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    Cox proportional hazard ratios. by Bryan S. Margulies (21492667)

    Published 2025
    “…Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. While many cytotoxic therapies increase p21 expression as a response to DNA damage, MBC-005 increased p21 expression independent cytotoxic DNA damage. …”
  10. 10

    Bioluminescent Doubling Time. by Bryan S. Margulies (21492667)

    Published 2025
    “…Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. While many cytotoxic therapies increase p21 expression as a response to DNA damage, MBC-005 increased p21 expression independent cytotoxic DNA damage. …”
  11. 11

    Study Design. by Bryan S. Margulies (21492667)

    Published 2025
    “…Intratumoral administration of MBC-005 increased survival 3.9-fold in mice and significantly decreased tumor volume 4-fold. While many cytotoxic therapies increase p21 expression as a response to DNA damage, MBC-005 increased p21 expression independent cytotoxic DNA damage. …”
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19

    Presentation 1_Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients.pptx by Alain Gelibter (6409364)

    Published 2024
    “…<p>Pembrolizumab (an anti-PD1 antibody) alone or combined with chemotherapy represented the standard of care for advanced non-oncogene addicted non-small cell lung cancer (NSCLC) patients. …”
  20. 20

    Table 1_Repurposing of the small-molecule adrenoreceptor-inhibitor carvedilol for treatment of the fibrotic lung.xlsx by Maria Jordan (10265489)

    Published 2025
    “…</p>Methods<p>In silico modeling of dysregulated pathways in IPF and screening for putative interfering small molecules identified carvedilol as a promising anti-fibrotic agent. …”